Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| U1111-1320-8718 | Registry Identifier | UTN | |
| 2025-521745-25-00 | Registry Identifier | EU CT | |
| MK-7240-014 | Other Identifier | MSD |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Researchers are looking for new ways to treat rheumatoid arthritis (RA). Methotrexate (MTX) is a standard (usual) treatment for RA. However, MTX and other current treatments may not work well to treat RA symptoms for many people.
This study will help find out if a study medicine called tulisokibart can treat symptoms of active RA in people who are taking MTX. In this study, researchers will look at different doses of tulisokibart.
Researchers want to learn if at least one of the study doses of tulisokibart works better than a placebo to lessen RA symptoms. A placebo looks like the study medicine but has no study medicine in it. Using a placebo helps researchers better understand the effects of the study medicine.
This study consists of a 12-week Placebo-controlled Period and a 116-week Long-term Extension (LTE), which is composed of a 44-week Main Extension and an 72-week Optional Extension
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| High-dose tulisokibart | Experimental | Participants receive background therapy of methotrexate (MTX) PLUS a high dose of tulisokibart |
|
| Medium-dose tulisokibart | Experimental | Participants receive background therapy of MTX PLUS a medium dose of tulisokibart. |
|
| Low-dose tulisokibart | Experimental | Participants receive background therapy of MTX PLUS a low dose of tulisokibart and are rerandomized at week 12 to a medium or high dose of tulisokibart. |
|
| Placebo | Placebo Comparator | Participants receive background therapy of MTX PLUS a dose-matched tulisokibart placebo and are re-randomized at week 12 to a medium or high dose of tulisokibart. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Tulisokibart | Drug | Subcutaneous (SC) administration |
|
| Measure | Description | Time Frame |
|---|---|---|
| Proportion of Participants Achieving American College of Rheumatology 20% Response Criteria (ACR20) at Week 12 | The ACR20 response is a composite measure to evaluate disease activity in RA. ACR20 response is defined as a ≥20% improvement in: a) swollen joint count (66 joints) and tender joint count (68 joints) (0= Absent; 1= Present) and b) ≥20% improvement in ≥3 of the following 5 assessments and questionnaires: i) Health Assessment Questionnaire Disability Index (HAQ-DI) (0=without any difficulty; 3= unable to do) a higher score=worse disability, ii) Physician Global Assessment of Disease Activity (PGA) (0= not active to 10= very active) a higher score= more active disease; iii) Patient's Global Assessment of Disease Activity (PtGA) (0= not active to 10= very active) a higher score= more active disease; iv) Patient assessment of Pain Severity (0= no pain to 10= most severe pain) a higher score = more pain; v) High-sensitivity C-reactive protein (hsCRP) serum values, a lower value indicates less inflammation. The proportion of participants with ACR20 response at Week 12 will be presented. | Week 12 |
| Measure | Description | Time Frame |
|---|---|---|
| Proportion of Participants Achieving American College of Rheumatology 50% Response Criteria (ACR50) at Week 12 | The ACR50 response is a composite measure to evaluate disease activity in RA. ACR50 response is defined as a ≥50% improvement in: a) swollen joint count (66 joints) and tender joint count (68 joints) (0= Absent; 1= Present) and b) ≥50% improvement in ≥3 of the following 5 assessments and questionnaires: i) Health Assessment Questionnaire Disability Index (HAQ-DI) (0= without any difficulty; 3= unable to do) a higher score=worse disability, ii) Physician Global Assessment of Disease Activity (PGA) (0= not active to 10= very active) a higher score= more active disease; iii) Patient's Global Assessment of Disease Activity (PtGA) (0= not active to 10= very active) a higher score= more active disease; iv) Patient assessment of Pain Severity (0= no pain to 10= most severe pain) a higher score = more pain; v) High-sensitivity C-reactive protein (hsCRP) serum values, a lower value indicates less inflammation. The proportion of participants with ACR50 response at Week 12 will be presented. |
Not provided
Inclusion Criteria:
The main inclusion criteria include but are not limited to the following:
Exclusion Criteria:
The main exclusion criteria include but are not limited to the following:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Medical Director | Merck Sharp & Dohme LLC | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Arizona Arthritis & Rheumatology Associates, P.C. ( Site 1018) | Glendale | Arizona | 85306-9802 | United States | ||
Not provided
| Label | URL |
|---|---|
| Merck Clinical Trials Information | View source |
| Plain Language Summary | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo | Drug | SC Injection |
|
| Methotrexate | Drug | Background Therapy - SC injection or oral administration. Per protocol, parenteral administration is allowed. |
|
|
| Week 12 |
| Proportion of Participants Achieving American College of Rheumatology 70% Response Criteria (ACR70) at Week 12 | The ACR70 response is a composite measure to evaluate disease activity in RA. ACR70 response is defined as a ≥70% improvement in: a) swollen joint count (66 joints) and tender joint count (68 joints) (0= Absent; 1= Present) and b) ≥70% improvement in ≥3 of the following 5 assessments and questionnaires: i) Health Assessment Questionnaire Disability Index (HAQ-DI) (0= without any difficulty; 3= unable to do) a higher score=worse disability, ii) Physician Global Assessment of Disease Activity (PGA) (0= not active to 10= very active) a higher score= more active disease; iii) Patient's Global Assessment of Disease Activity (PtGA) (0= not active to 10= very active) a higher score= more active disease; iv) Patient assessment of Pain Severity (0= no pain to 10= most severe pain) a higher score = more pain; v) High-sensitivity C-reactive protein (hsCRP) serum values, a lower value indicates less inflammation. The proportion of participants with ACR70 response at Week 12 will be presented. | Week 12 |
| Proportion of Participants Achieving Low Disease Activity (LDA) based on Disease Activity Score 28 Using C-Reactive Protein (DAS28-CRP) | The DAS28-CRP is a composite measure of RA disease activity. DAS28-CRP is based upon a statistically-derived index combining the following 4 components: i) tender joint count (TJC) (28 joints; 0=absent, 1=present; TJC28), ii) swollen joint count (SJC) (28 joints; 0=absent, 1=present; SJC28), iii) serum high-sensitivity C-reactive protein (hsCRP), serum value decrease indicates less inflammation, and iv) Patient's Global Assessment of Disease Activity (PtGA) (0= not active to 10= very active) a higher score= more active disease. The index is defined as follows: DAS28-CRP = 0.56 × SQRT(TJC28) + 0.28 × SQRT(SJC28) + 0.36 × ln (hsCRP+1) + 0.014 × ptGA+ 0.96. The DAS28-CRP is a scale ranging from 0 to 10 with higher values indicating greater RA disease activity. Remission is indicated by a DAS28-CRP score of <2.6 and low disease activity (LDA) by a DAS28-CRP score of ≤3.2. The proportion of participants who achieve LDA will be presented. | Week 12 |
| Change From Baseline in the Health Assessment Questionnaire Disability Index (HAQ-DI) Score at Week 12 | The HAQ-DI is a 20-item questionnaire that measures physical function in participants with RA. The questionnaire assesses the degree of difficulty a person has in accomplishing tasks in 8 functional area domains (dressing and grooming, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area domain are scored from 0 to 3 (0= without any difficulty; 3= unable to do), with a higher score indicating inability to perform activity. The overall disability score (HAQ-DI) is a summation of the highest score from each domain divided by the number of domains completed and ranges from 0 to 3, with the higher value indicating worse disability. The change from baseline to week 12 in the HAQ-DI score will be presented. | Baseline and Week 12 |
| Number of Participants Who Experience One or More Adverse Events (AEs) | An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. | Up to approximately Week 142 |
| Number of Participants Who Discontinue Study Intervention Due to an AE | An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study intervention due to an AE will be reported. | Up to approximately Week 128 |
| AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Mesa ( Site 1033) |
| Mesa |
| Arizona |
| 85210 |
| United States |
| Arthritis & Osteoporosis Medical Center - La Palma ( Site 1024) | La Palma | California | 90623 | United States |
| Tekton Research, LLC. ( Site 1008) | Fort Collins | Colorado | 80528 | United States |
| Sweet Hope Research Specialty, Inc ( Site 1015) | Hialeah | Florida | 33016 | United States |
| HMD Research LLC ( Site 1016) | Orlando | Florida | 32819 | United States |
| Greater Chicago Specialty Physicians - Orland Park ( Site 1043) | Orland Park | Illinois | 60467 | United States |
| AA Medical Research Center ( Site 1027) | Grand Blanc | Michigan | 48439 | United States |
| Kansas City Physician Partners ( Site 1032) | Kansas City | Missouri | 64111 | United States |
| Physician Research Collaboration, LLC ( Site 1002) | Lincoln | Nebraska | 68516 | United States |
| altoona center for clinical research ( Site 1005) | Duncansville | Pennsylvania | 16635 | United States |
| Rheumatology Specialty Center ( Site 1030) | Willow Grove | Pennsylvania | 19090 | United States |
| AARA Clinical Research - Murfreesboro Medical Clinic ( Site 1034) | Murfreesboro | Tennessee | 37128 | United States |
| Rheumatology Associates ( Site 1026) | Arlington | Texas | 76012 | United States |
| Epic Medical Research ( Site 1004) | Red Oak | Texas | 75154 | United States |
| Advanced Rheumatology of Houston - Woodlands ( Site 1000) | The Woodlands | Texas | 77382 | United States |
| Mount Sinai Hospital ( Site 1102) | Toronto | Ontario | M5T 3L9 | Canada |
| CIUSSS de l'Estrie - CHUS, Hotel-Dieu de Sherbrooke ( Site 1106) | Sherbrooke | Quebec | J1G 2E8 | Canada |
| Centre de Recherche Musculo-Squelettique ( Site 1101) | Trois-Rivières | Quebec | G9A 3X2 | Canada |
| Centro de Estudios GyC ( Site 1206) | Santiago | Region M. de Santiago | 7500504 | Chile |
| Clinica Dermacross ( Site 1203) | Santiago | Region M. de Santiago | 7640881 | Chile |
| CECIM ( Site 1208) | Santiago | Region M. de Santiago | 8320000 | Chile |
| Pontificia Universidad Catolica de Chile-CICUC ( Site 1209) | Santiago | Region M. de Santiago | 8330073 | Chile |
| Peking University First Hospital ( Site 2511) | Beijing | Beijing Municipality | 100034 | China |
| The First Affiliated Hospital of Xiamen University. ( Site 2510) | Xiamen | Fujian | 361003 | China |
| The Third Affiliated Hospital, Sun Yat-sen University ( Site 2514) | Guangzhou | Guangdong | 510630 | China |
| Xinxiang Central Hospital ( Site 2501) | Xinxiang | Henan | 453000 | China |
| Pingxiang People's Hospital ( Site 2512) | Pingxiang | Jiangxi | 337000 | China |
| Linfen Central Hospital ( Site 2507) | Linfen | Shanxi | 041000 | China |
| PEOPLE'S HOSPITAL OF XINJIANG UYGUR AUTONOMOUS REGION ( Site 2515) | Ürümqi | Xinjiang | 830001 | China |
| Taizhou Hospital of Zhejiang Province ( Site 2506) | Linhai | Zhejiang | 317000 | China |
| Clinica de la Costa S.A.S. ( Site 1301) | Barranquilla | Atlántico | 080020 | Colombia |
| CIREEM SAS ( Site 1304) | Bogota | Cundinamarca | 110111 | Colombia |
| Fundación Valle del Lili ( Site 1305) | Cali | Valle del Cauca Department | 760032 | Colombia |
| Medicover München Ost MVZ ( Site 1607) | München | Bavaria | 81667 | Germany |
| Rheuma-Research Lausitz ( Site 1604) | Cottbus | Brandenburg | 03042 | Germany |
| Rheumazentrum Ratingen Studienambulanz ( Site 1601) | Ratingen | North Rhine-Westphalia | 40878 | Germany |
| Rheumatologische Schwerpunktpraxis ( Site 1603) | Berlin | 12161 | Germany |
| HRF II - Hamburger Rheuma Forschungszentrum II MVZ für Rheumatologie und Autoimmunmedizin Hamburg G ( Site 1602) | Hamburg | 20095 | Germany |
| Toshin Yoshida Internal Medicine Rheumatology ( Site 2606) | Hanishina-gun | Nagano | 389-0606 | Japan |
| Sasebo Chuo Hospital ( Site 2602) | Sasebo | Nagasaki | 857-1195 | Japan |
| Nagaoka Red Cross Hospital ( Site 2604) | Nagaoka | Niigata | 940-2085 | Japan |
| Hirose Clinic ( Site 2601) | Tokorozawa | Saitama | 359-1111 | Japan |
| University of Yamanashi Hospital ( Site 2603) | Chūō | Yamanashi | 409-3898 | Japan |
| Kai Clinic ( Site 2600) | Miyazaki | 880-0053 | Japan |
| MICS Centrum Medyczne Bydgoszcz ( Site 1807) | Bydgoszcz | Kuyavian-Pomeranian Voivodeship | 85-065 | Poland |
| Szpital Uniwersytecki nr 2 im. Dr. Jana Biziela-Klnk Reumatologii i Ukladowych Chorob Tkanki Lacznej ( Site 1804) | Bydgoszcz | Kuyavian-Pomeranian Voivodeship | 85-168 | Poland |
| MICS Centrum Medyczne Torun ( Site 1803) | Torun | Kuyavian-Pomeranian Voivodeship | 87-100 | Poland |
| Zespół Poradni Specjalistycznych Reumed Filia nr 1 Wallenroda ( Site 1801) | Lublin | Lublin Voivodeship | 20-607 | Poland |
| MICS Centrum Medyczne Warszawa ( Site 1805) | Warsaw | Masovian Voivodeship | 00-874 | Poland |
| Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji ( Site 1806) | Warsaw | Masovian Voivodeship | 02-637 | Poland |
| NZOZ BIF-MED ( Site 1802) | Bytom | Silesian Voivodeship | 41-902 | Poland |
| Soon Chun Hyang University Cheonan Hospital ( Site 2304) | Cheonan-si | Chungcheongnam-do | 31151 | South Korea |
| Chungnam national university hospital ( Site 2303) | Daejeon | Taejon-Kwangyokshi | 35015 | South Korea |
| Hanyang University Seoul Hospital ( Site 2300) | Seoul | 04763 | South Korea |
| Hospital Universitari Parc Tauli ( Site 1900) | Sabadell | Barcelona | 8208 | Spain |
| Hospital Universitario Marqués de Valdecilla ( Site 1906) | Santander | Cantabria | 39008 | Spain |
| Hospital Clinico Universitario de Santiago ( Site 1903) | Santiago de Compostela | La Coruna | 15706 | Spain |
| Hospital Universitari Vall d'Hebron ( Site 1901) | Barcelona | 08035 | Spain |
| The Princess Alexandra Hospital NHS Trust ( Site 2103) | Harlow | England | CM20 1QX | United Kingdom |
| Chapel Allerton Hospital ( Site 2106) | Leeds | LS7 4SA | United Kingdom |
| Barnet Hospital ( Site 2102) | London | EN5 3DJ | United Kingdom |
| ID | Term |
|---|---|
| D001172 | Arthritis, Rheumatoid |
| ID | Term |
|---|---|
| D001168 | Arthritis |
| D007592 | Joint Diseases |
| D009140 | Musculoskeletal Diseases |
| D012216 | Rheumatic Diseases |
| D003240 | Connective Tissue Diseases |
| D017437 | Skin and Connective Tissue Diseases |
| D001327 | Autoimmune Diseases |
| D007154 | Immune System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D008727 | Methotrexate |
| ID | Term |
|---|---|
| D000630 | Aminopterin |
| D011622 | Pterins |
| D011621 | Pteridines |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D006571 | Heterocyclic Compounds |
Not provided
Not provided